Loading clinical trials...

Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital | Clinical Trials | Clareo Health

RECRUITINGNA

Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital

Closed Loop Oxygen Control in COPD Patients Treated With Nasal High Flow in the Hospital

NCT07222410•Fisher and Paykel Healthcare

View on ClinicalTrials.gov

Summary

The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.

Eligibility

Age

22 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Has cognitive ability to provide informed consent
•Aged 22 years or older
•Hospitalized with hypoxemia/respiratory distress
•Diagnosis of COPD
•Candidate for/currently prescribed nasal high flow (flow rate of at least 25 L/min) with supplemental oxygen, as assessed by the investigator
•Expected duration of oxygen and nasal high flow therapy \>24 hours (not necessarily continuous)

Exclusion Criteria

•Receiving Non Invasive Ventilation (NIV) or indicated for NIV as per European Respiratory Society /American Thoracic Society guidelines
•Hemodynamic instability (systolic blood pressure \<90mmHg or requirement for vasopressor or inotropic support)
•Patient receiving end of life care
•Nasal or facial conditions precluding use of nasal high flow
•Pregnancy or breastfeeding
•Cognitive impairment or impaired consciousness precluding informed consent
•Unsuitable for adhesive finger pulse oximetry, as assessed by the investigator
•Any other condition which, at the investigator's discretion, is believed to present a safety risk to the patient if included
•The presence of any active comorbidities that affect the patient's condition importantly in the next 30 days, as assessed by the investigator
•Has already participated in this clinical trial

Locations (1)

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Key Dates

Start Date

January 7, 2026

Primary Completion Date

November 1, 2027

Completion Date

November 1, 2027

Last Updated

January 12, 2026

Enrollment

ESTIMATED participants

Conditions

COPD

Interventions

Closed loop oxygen control

DEVICE

Manual titration

DEVICE

Contacts

Jenny Han

CONTACT

64 9 574 0123 optio2trial@fphcare.com

cfMSC Stem Cell Therapy Targeting COPD

NCT07477600

Chronic Obstructive Pulmonary Disease (COPD)

View study

RECRUITINGNA

Effect of Telenursing on Oral Health

NCT07462221

COPD

View study

RECRUITINGNA

Emotional-distress-based Integrated Care Programme in Patients With an Acute Exacerbation of COPD

NCT07351929

COPD Exacerbation

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 12, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital

Inclusion Criteria

Exclusion Criteria

cfMSC Stem Cell Therapy Targeting COPD

Effect of Telenursing on Oral Health

Emotional-distress-based Integrated Care Programme in Patients With an Acute Exacerbation of COPD

Probiotics in Pulmonaty Rehabilitation for COPD

Effects of Eccentric Exercise Training in Patients With COPD

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3